Alembic Pharmaceuticals LimitedNSE: APLLTD

Press Release Apr 07 2022

· Issued by Alembic Pharmaceuticals Limited

Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 31-Mar-2022 titled Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg.

View Attachment

6ix hasn’t read this filing yet.

Alembic Pharmaceuticals Limited on 6ix

Earlier from Alembic Pharmaceuticals

Later from Alembic Pharmaceuticals

All Alembic Pharmaceuticals news releases